Deals
Zentalis Pharmaceuticals Climbs in Debut After Expanded IPO
This article is for subscribers only.
Zentalis Pharmaceuticals Inc., a clinical-stage cancer treatment developer, rose 29% in its trading debut after raising about $165 million in an initial public offering.
The company’s shares, which surged as much as 50% from the $18 offer price, closed Friday at $23.20, giving the firm a market value of $798 million. Zentalis sold 9.18 million shares on Thursday at the top of a marketed range, after expanding the IPO from 7.65 million shares.